Labcorp and Quest Shares Fall on CMS 2027 Lab Rate Cuts

Key Facts

1Labcorp and Quest shares declined following the CMS announcement of rate cuts for laboratory services effective in 2027.

Amid shifting regulatory landscapes in the U.S. healthcare sector, diagnostic laboratory providers are facing renewed pressure on their long-term outlooks. Shares of Labcorp Holdings Inc. and Quest Diagnostics declined following an announcement from the Centers for Medicare & Medicaid Services (CMS) regarding rate cuts for laboratory services effective in 2027. According to reports, the regulatory update directly impacts future revenue streams by lowering the reimbursement rates the companies can claim for diagnostic testing.

The market reaction underscores sensitivity to government-led pricing adjustments which threaten to compress industry margins. Per market data, Labcorp (LH) stood at $320.71 at close on September 18, 2026, having traded within a range of $319.38 to $322.7 during that session. This downward movement reflects broader concerns over how major diagnostic labs will offset the impact of reduced federal payments in the coming years.

Investors are now watching for stability around the $319.38 support level, which marked the day's low at close on September 18, 2026. While the upcoming economic calendar is dominated by international trade and manufacturing data, the primary catalyst for these instruments remains further clarity from CMS regarding the final implementation of the 2027 rate schedule.